Rationale, design, and baseline characteristics in evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo

Rhonda Bentley-Lewis, David Aguilar, Matthew C. Riddle, Brian Claggett, Rafael Diaz, Kenneth Dickstein, Hertzel C. Gerstein, Peter Johnston, Lars V. Køber, Francesca Lawson, Eldrin F. Lewis, Aldo P. Maggioni, John J. V. McMurray, Lin Ping, Jeffrey L. Probstfield, Scott D. Solomon, Jean-Claude Tardif, Yujun Wu, Marc A. Pfeffer, ELIXA InvestigatorsChristian Torp-Pedersen

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

66 Citationer (Scopus)
OriginalsprogEngelsk
TidsskriftAmerican Heart Journal
Vol/bind169
Udgave nummer5
Sider (fra-til)631-638.e7
Antal sider15
ISSN0002-8703
DOI
StatusUdgivet - 2015

Citationsformater

Bentley-Lewis, R., Aguilar, D., Riddle, M. C., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Johnston, P., Køber, L. V., Lawson, F., Lewis, E. F., Maggioni, A. P., McMurray, J. J. V., Ping, L., Probstfield, J. L., Solomon, S. D., Tardif, J-C., Wu, Y., Pfeffer, M. A., ... Torp-Pedersen, C. (2015). Rationale, design, and baseline characteristics in evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. American Heart Journal, 169(5), 631-638.e7. https://doi.org/10.1016/j.ahj.2015.02.002